{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:29Z","timestamp":1793035889105,"version":"4.5.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00296-022-05136-x","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T09:03:48Z","timestamp":1651568628000},"page":"1493-1511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-3093","authenticated-orcid":false,"given":"Gerasimos","family":"Evangelatos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-5717","authenticated-orcid":false,"given":"Giorgos","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-6176","authenticated-orcid":false,"given":"George D.","family":"Kitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1867-3150","authenticated-orcid":false,"given":"George","family":"Kollias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"5136_CR1","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025\u20134031","journal-title":"EMBO J"},{"key":"5136_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF (2021) Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 385:628\u2013639. https:\/\/doi.org\/10.1056\/NEJMra1909094","journal-title":"N Engl J Med"},{"key":"5136_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000289205","volume":"11","author":"PP Sfikakis","year":"2010","unstructured":"Sfikakis PP (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 11:180\u2013210. https:\/\/doi.org\/10.1159\/000289205","journal-title":"Curr Dir Autoimmun"},{"key":"5136_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/286857","volume":"2013","author":"D Sanchez-Cano","year":"2013","unstructured":"Sanchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R et al (2013) Off-label uses of anti-TNF therapy in three frequent disorders: Behcet\u2019s disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm 2013:286857. https:\/\/doi.org\/10.1155\/2013\/286857","journal-title":"Mediators Inflamm"},{"key":"5136_CR5","doi-asserted-by":"publisher","unstructured":"Shuai ZQ, Zhang CX, Shuai ZW, et al (2021) Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25: 250\u201362. https:\/\/doi.org\/10.26355\/eurrev_202101_24391.","DOI":"10.26355\/eurrev_202101_24391"},{"key":"5136_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.091086","volume":"37","author":"K Ben Abdelghani","year":"2010","unstructured":"Ben Abdelghani K, Dran DG, Gottenberg JE et al (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37:1699\u20131704. https:\/\/doi.org\/10.3899\/jrheum.091086","journal-title":"J Rheumatol"},{"key":"5136_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14976","volume":"34","author":"Y Ge","year":"2021","unstructured":"Ge Y, Li S, Chen F et al (2021) The effects of infliximab in treating idiopathic inflammatory myopathies: a review article. Dermatol Ther 34:e14976. https:\/\/doi.org\/10.1111\/dth.14976","journal-title":"Dermatol Ther"},{"key":"5136_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-021-00160-x","author":"AS Melani","year":"2021","unstructured":"Melani AS, Bigliazzi C, Cimmino FA et al (2021) A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. https:\/\/doi.org\/10.1007\/s41030-021-00160-x","journal-title":"Pulm Ther"},{"key":"5136_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102784","volume":"20","author":"E Conticini","year":"2021","unstructured":"Conticini E, Sota J, Falsetti P et al (2021) Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: a narrative review. Autoimmun Rev 20:102784. https:\/\/doi.org\/10.1016\/j.autrev.2021.102784","journal-title":"Autoimmun Rev"},{"key":"5136_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.030","author":"NT Deuitch","year":"2021","unstructured":"Deuitch NT, Yang D, Lee PY et al (2021) TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2). J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.030","journal-title":"J Allergy Clin Immunol"},{"key":"5136_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","volume":"6","author":"E Maverakis","year":"2020","unstructured":"Maverakis E, Marzano AV, Le ST et al (2020) Pyoderma gangrenosum. Nat Rev Dis Primers 6:81. https:\/\/doi.org\/10.1038\/s41572-020-0213-x","journal-title":"Nat Rev Dis Primers"},{"key":"5136_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000065","volume":"1","author":"M Manara","year":"2015","unstructured":"Manara M, Sinigaglia L (2015) Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open 1:e000065. https:\/\/doi.org\/10.1136\/rmdopen-2015-000065","journal-title":"RMD Open"},{"key":"5136_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.150642","volume":"93","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Possemato N, Caruso A et al (2015) The role of tumor necrosis factor-alpha blockers in psoriatic disease. therapeutic options in psoriatic arthritis. J Rheumatol Suppl 93:73\u201378. https:\/\/doi.org\/10.3899\/jrheum.150642","journal-title":"J Rheumatol Suppl"},{"key":"5136_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG et al (2017) Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther 45:3\u201313. https:\/\/doi.org\/10.1111\/apt.13847","journal-title":"Aliment Pharmacol Ther"},{"key":"5136_CR15","doi-asserted-by":"publisher","unstructured":"Bournia VK, Fragoulis GE, Mitrou P, et al (2021) All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015\u20132019. RMD Open 7 https:\/\/doi.org\/10.1136\/rmdopen-2021-001694.","DOI":"10.1136\/rmdopen-2021-001694"},{"key":"5136_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"5136_CR17","doi-asserted-by":"publisher","unstructured":"Salesi M, Shojaie B, Farajzadegan Z, et al (2021) TNF-alpha Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study. Rheumatol Ther: 1-16. https:\/\/doi.org\/10.1007\/s40744-021-00342-8","DOI":"10.1007\/s40744-021-00342-8"},{"key":"5136_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.808608","volume":"8","author":"BDC Gracia","year":"2021","unstructured":"Gracia BDC, Saez L, Pallares L et al (2021) COVID GEAS: COVID-19 national survey in patients with systemic autoimmune diseases. Front Med (Lausanne) 8:808608. https:\/\/doi.org\/10.3389\/fmed.2021.808608","journal-title":"Front Med (Lausanne)"},{"key":"5136_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/apt.16717","volume":"55","author":"G Kokkotis","year":"2022","unstructured":"Kokkotis G, Kitsou K, Xynogalas I et al (2022) Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther 55:154\u2013167. https:\/\/doi.org\/10.1111\/apt.16717","journal-title":"Aliment Pharmacol Ther"},{"key":"5136_CR20","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","volume":"2","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Richards D, Tanner HL et al (2020) Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2:e653\u2013e655. https:\/\/doi.org\/10.1016\/S2665-9913(20)30309-X","journal-title":"Lancet Rheumatol"},{"key":"5136_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"5136_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H et al (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5136_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clim.2011.09.005","volume":"141","author":"PP Sfikakis","year":"2011","unstructured":"Sfikakis PP, Tsokos GC (2011) Towards the next generation of anti-TNF drugs. Clin Immunol 141:231\u2013235. https:\/\/doi.org\/10.1016\/j.clim.2011.09.005","journal-title":"Clin Immunol"},{"key":"5136_CR24","doi-asserted-by":"publisher","unstructured":"Sakkou M, Chouvardas P, Ntari L, et al (2018) Mesenchymal TNFR2 promotes the development of polyarthritis and comorbid heart valve stenosis. JCI Insight 3 https:\/\/doi.org\/10.1172\/jci.insight.98864.","DOI":"10.1172\/jci.insight.98864"},{"key":"5136_CR25","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-021-01065-2","volume":"22","author":"B Wu","year":"2021","unstructured":"Wu B, Zhao TV, Jin K et al (2021) Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nat Immunol 22:1551\u20131562. https:\/\/doi.org\/10.1038\/s41590-021-01065-2","journal-title":"Nat Immunol"},{"key":"5136_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41467-018-02935-4","volume":"9","author":"M Armaka","year":"2018","unstructured":"Armaka M, Ospelt C, Pasparakis M et al (2018) The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts. Nat Commun 9:618. https:\/\/doi.org\/10.1038\/s41467-018-02935-4","journal-title":"Nat Commun"},{"key":"5136_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1084\/jem.20070906","volume":"205","author":"M Armaka","year":"2008","unstructured":"Armaka M, Apostolaki M, Jacques P et al (2008) Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 205:331\u2013337. https:\/\/doi.org\/10.1084\/jem.20070906","journal-title":"J Exp Med"},{"key":"5136_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/annrheumdis-2017-212597","volume":"77","author":"L Ntari","year":"2018","unstructured":"Ntari L, Sakkou M, Chouvardas P et al (2018) Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis. Ann Rheum Dis 77:926\u2013934. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212597","journal-title":"Ann Rheum Dis"},{"key":"5136_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","volume":"21","author":"S Davidson","year":"2021","unstructured":"Davidson S, Coles M, Thomas T et al (2021) Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol 21:704\u2013717. https:\/\/doi.org\/10.1038\/s41577-021-00540-z","journal-title":"Nat Rev Immunol"},{"key":"5136_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft AP, Campos J, Jansen K et al (2019) Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570:246\u2013251. https:\/\/doi.org\/10.1038\/s41586-019-1263-7","journal-title":"Nature"},{"key":"5136_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","volume":"582","author":"K Wei","year":"2020","unstructured":"Wei K, Korsunsky I, Marshall JL et al (2020) Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582:259\u2013264. https:\/\/doi.org\/10.1038\/s41586-020-2222-z","journal-title":"Nature"},{"key":"5136_CR32","doi-asserted-by":"publisher","unstructured":"Armaka M, Konstantopoulos D, Tzaferis C, et al (2021) https:\/\/doi.org\/10.1101\/2021.08.27.457747.","DOI":"10.1101\/2021.08.27.457747"},{"key":"5136_CR33","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/art.23653","volume":"58","author":"M Tunyogi-Csapo","year":"2008","unstructured":"Tunyogi-Csapo M, Kis-Toth K, Radacs M et al (2008) Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 58:2397\u20132408. https:\/\/doi.org\/10.1002\/art.23653","journal-title":"Arthritis Rheum"},{"key":"5136_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163. https:\/\/doi.org\/10.1038\/nm1538","journal-title":"Nat Med"},{"key":"5136_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fimmu.2014.00048","volume":"5","author":"B Osta","year":"2014","unstructured":"Osta B, Benedetti G, Miossec P (2014) Classical and paradoxical effects of TNF-alpha on bone homeostasis. Front Immunol 5:48. https:\/\/doi.org\/10.3389\/fimmu.2014.00048","journal-title":"Front Immunol"},{"key":"5136_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fimmu.2019.00679","volume":"10","author":"F Coury","year":"2019","unstructured":"Coury F, Peyruchaud O, Machuca-Gayet I (2019) Osteoimmunology of bone loss in inflammatory rheumatic diseases. Front Immunol 10:679. https:\/\/doi.org\/10.3389\/fimmu.2019.00679","journal-title":"Front Immunol"},{"key":"5136_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese EM, Schett G (2018) Effects of the IL-23\u2013IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14:631\u2013640. https:\/\/doi.org\/10.1038\/s41584-018-0091-8","journal-title":"Nat Rev Rheumatol"},{"key":"5136_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","volume":"28","author":"CAF Zerbini","year":"2017","unstructured":"Zerbini CAF, Clark P, Mendez-Sanchez L et al (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429\u2013446. https:\/\/doi.org\/10.1007\/s00198-016-3769-2","journal-title":"Osteoporos Int"},{"key":"5136_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10067-013-2263-x","volume":"32","author":"M Konsta","year":"2013","unstructured":"Konsta M, Sfikakis PP, Bournia VK et al (2013) Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. Clin Rheumatol 32:1229\u20131232. https:\/\/doi.org\/10.1007\/s10067-013-2263-x","journal-title":"Clin Rheumatol"},{"key":"5136_CR40","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/annrheumdis-2013-203963","volume":"73","author":"TW Nystad","year":"2014","unstructured":"Nystad TW, Furnes O, Havelin LI et al (2014) Hip replacement surgery in patients with ankylosing spondylitis. Ann Rheum Dis 73:1194\u20131197. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203963","journal-title":"Ann Rheum Dis"},{"key":"5136_CR41","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.2147\/IJGM.S336314","volume":"14","author":"L Li","year":"2021","unstructured":"Li L, Fu J, Xu C et al (2021) Hip Replacement in ankylosing spondylitis patients with advanced hip involvement: factors associated with bilateral total hip arthroplasty. Int J Gen Med 14:6857\u20136862. https:\/\/doi.org\/10.2147\/IJGM.S336314","journal-title":"Int J Gen Med"},{"key":"5136_CR42","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/rheumatology\/key424","volume":"58","author":"S Hawley","year":"2019","unstructured":"Hawley S, Ali MS, Cordtz R et al (2019) Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology (Oxford) 58:1168\u20131175. https:\/\/doi.org\/10.1093\/rheumatology\/key424","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12891-017-1685-z","volume":"18","author":"YC Chen","year":"2017","unstructured":"Chen YC, Chiu WC, Cheng TT et al (2017) Delayed anti-TNF therapy increases the risk of total knee replacement in patients with severe rheumatoid arthritis. BMC Musculoskelet Disord 18:326. https:\/\/doi.org\/10.1186\/s12891-017-1685-z","journal-title":"BMC Musculoskelet Disord"},{"key":"5136_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3899\/jrheum.100925","volume":"38","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, Chiowchanwisawakit P, Lambert RG et al (2011) Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 38:1349\u20131354. https:\/\/doi.org\/10.3899\/jrheum.100925","journal-title":"J Rheumatol"},{"key":"5136_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Haibel H, Listing J et al (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8\u00a0years in patients with ankylosing spondylitis. Ann Rheum Dis 73:710\u2013715. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202698","journal-title":"Ann Rheum Dis"},{"key":"5136_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105111","volume":"88","author":"M Konsta","year":"2021","unstructured":"Konsta M, Sakellariou GT, Rusman T et al (2021) Long-term effect of TNF inhibitors on radiographic progression in ankylosing spondylitis is associated with time-averaged CRP levels. Joint Bone Spine 88:105111. https:\/\/doi.org\/10.1016\/j.jbspin.2020.105111","journal-title":"Joint Bone Spine"},{"key":"5136_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","volume":"39","author":"K Gulyas","year":"2020","unstructured":"Gulyas K, Horvath A, Vegh E et al (2020) Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39:167\u2013175. https:\/\/doi.org\/10.1007\/s10067-019-04771-3","journal-title":"Clin Rheumatol"},{"key":"5136_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-019-0818-9","volume":"21","author":"D Ashany","year":"2019","unstructured":"Ashany D, Stein EM, Goto R et al (2019) The effect of TNF inhibition on bone density and fracture risk and of IL17 Inhibition on radiographic progression and bone density in patients with axial spondyloarthritis: a systematic literature review. Curr Rheumatol Rep 21:20. https:\/\/doi.org\/10.1007\/s11926-019-0818-9","journal-title":"Curr Rheumatol Rep"},{"key":"5136_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jocd.2018.07.010","volume":"22","author":"MB Maldonado-Perez","year":"2019","unstructured":"Maldonado-Perez MB, Castro-Laria L, Caunedo-Alvarez A et al (2019) Does the antitumor necrosis factor-alpha therapy decrease the vertebral fractures occurrence in inflammatory bowel disease? J Clin Densitom 22:195\u2013202. https:\/\/doi.org\/10.1016\/j.jocd.2018.07.010","journal-title":"J Clin Densitom"},{"key":"5136_CR50","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/jgh.15084","volume":"35","author":"M Guasch","year":"2020","unstructured":"Guasch M, Canete F, Ordas I et al (2020) Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. J Gastroenterol Hepatol 35:2080\u20132087. https:\/\/doi.org\/10.1111\/jgh.15084","journal-title":"J Gastroenterol Hepatol"},{"key":"5136_CR51","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","volume":"63","author":"C Rungoe","year":"2014","unstructured":"Rungoe C, Langholz E, Andersson M et al (2014) Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979\u20132011. Gut 63:1607\u20131616. https:\/\/doi.org\/10.1136\/gutjnl-2013-305607","journal-title":"Gut"},{"key":"5136_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/MPG.0000000000003301","volume":"74","author":"G D'Arcangelo","year":"2022","unstructured":"D\u2019Arcangelo G, Abi Nader E, Charbit-Henrion F et al (2022) Increased use of anti-tumor necrosis factor following the implementation of the ECCO-ESPGHAN guidelines and its impact on the outcome of pediatric crohn\u2019s disease: a retrospective single-center study. J Pediatr Gastroenterol Nutr 74:79\u201384. https:\/\/doi.org\/10.1097\/MPG.0000000000003301","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5136_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","author":"T Raine","year":"2021","unstructured":"Raine T, Bonovas S, Burisch J et al (2021) ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"5136_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G et al (2020) ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohns Colitis 14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180","journal-title":"J Crohns Colitis"},{"key":"5136_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","volume":"10","author":"K Karmiris","year":"2016","unstructured":"Karmiris K, Avgerinos A, Tavernaraki A et al (2016) Prevalence and characteristics of extra-intestinal manifestations in a large cohort of greek patients with inflammatory bowel disease. J Crohns Colitis 10:429\u2013436. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv232","journal-title":"J Crohns Colitis"},{"key":"5136_CR56","doi-asserted-by":"publisher","unstructured":"Arida A, Protogerou AD, Kitas GD, et al (2018) Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. Int J Mol Sci 19 https:\/\/doi.org\/10.3390\/ijms19071890.","DOI":"10.3390\/ijms19071890"},{"key":"5136_CR57","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/rheumatology\/kew506","volume":"56","author":"A Arida","year":"2017","unstructured":"Arida A, Protogerou AD, Konstantonis G et al (2017) Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford) 56:934\u2013939. https:\/\/doi.org\/10.1093\/rheumatology\/kew506","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR58","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.3899\/jrheum.150316","volume":"42","author":"A Arida","year":"2015","unstructured":"Arida A, Protogerou AD, Konstantonis G et al (2015) Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol 42:2098\u20132105. https:\/\/doi.org\/10.3899\/jrheum.150316","journal-title":"J Rheumatol"},{"key":"5136_CR59","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/rheumatology\/ket454","volume":"53","author":"LS Tam","year":"2014","unstructured":"Tam LS, Kitas GD, Gonzalez-Gay MA (2014) Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 53:1108\u20131119. https:\/\/doi.org\/10.1093\/rheumatology\/ket454","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR60","doi-asserted-by":"publisher","first-page":"13205","DOI":"10.1038\/s41598-018-31550-y","volume":"8","author":"B Batko","year":"2018","unstructured":"Batko B, Maga P, Urbanski K et al (2018) Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment. Sci Rep 8:13205. https:\/\/doi.org\/10.1038\/s41598-018-31550-y","journal-title":"Sci Rep"},{"key":"5136_CR61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ijcard.2018.06.099","volume":"270","author":"NAB Ntusi","year":"2018","unstructured":"Ntusi NAB, Francis JM, Sever E et al (2018) Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol 270:253\u2013259. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.099","journal-title":"Int J Cardiol"},{"key":"5136_CR62","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"AS Low","year":"2017","unstructured":"Low AS, Symmons DP, Lunt M et al (2017) Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76:654\u2013660. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209784","journal-title":"Ann Rheum Dis"},{"key":"5136_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00296-020-04666-6","volume":"41","author":"IAM van den Oever","year":"2021","unstructured":"van den Oever IAM, Baniaamam M, Simsek S et al (2021) The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int 41:319\u2013328. https:\/\/doi.org\/10.1007\/s00296-020-04666-6","journal-title":"Rheumatol Int"},{"key":"5136_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00296-018-4183-1","volume":"39","author":"J Veldhuijzen van Zanten","year":"2019","unstructured":"Veldhuijzen van Zanten J, Sandoo A, Metsios GS et al (2019) Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: results from two controlled trials. Rheumatol Int 39:219\u2013225. https:\/\/doi.org\/10.1007\/s00296-018-4183-1","journal-title":"Rheumatol Int"},{"key":"5136_CR65","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/rheumatology\/key013","volume":"57","author":"A Abhishek","year":"2018","unstructured":"Abhishek A, Nakafero G, Kuo CF et al (2018) Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink. Rheumatology (Oxford) 57:977\u2013981. https:\/\/doi.org\/10.1093\/rheumatology\/key013","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT et al (2020) Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther 37:364\u2013380. https:\/\/doi.org\/10.1007\/s12325-019-01145-8","journal-title":"Adv Ther"},{"key":"5136_CR67","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895\u20131904. https:\/\/doi.org\/10.1136\/ard.2010.149419","journal-title":"Ann Rheum Dis"},{"key":"5136_CR68","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886\u20132895. https:\/\/doi.org\/10.1002\/art.22864","journal-title":"Arthritis Rheum"},{"key":"5136_CR69","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.2007.085852","volume":"68","author":"J Askling","year":"2009","unstructured":"Askling J, Baecklund E, Granath F et al (2009) Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:648\u2013653. https:\/\/doi.org\/10.1136\/ard.2007.085852","journal-title":"Ann Rheum Dis"},{"key":"5136_CR70","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Galloway JB, Lunt M et al (2017) Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 76:497\u2013503. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209389","journal-title":"Ann Rheum Dis"},{"key":"5136_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","volume":"76","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Dreyer L, Arkema EV et al (2017) Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis 76:105\u2013111. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209270","journal-title":"Ann Rheum Dis"},{"key":"5136_CR72","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63:1479\u20131485. https:\/\/doi.org\/10.1002\/art.30310","journal-title":"Arthritis Rheum"},{"key":"5136_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","volume":"72","author":"L Dreyer","year":"2013","unstructured":"Dreyer L, Mellemkjaer L, Andersen AR et al (2013) Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis 72:79\u201382. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201969","journal-title":"Ann Rheum Dis"},{"key":"5136_CR74","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"N Nyboe Andersen","year":"2014","unstructured":"Nyboe Andersen N, Pasternak B, Basit S et al (2014) Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 311:2406\u20132413. https:\/\/doi.org\/10.1001\/jama.2014.5613","journal-title":"JAMA"},{"key":"5136_CR75","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","volume":"50","author":"W Amari","year":"2011","unstructured":"Amari W, Zeringue AL, McDonald JR et al (2011) Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 50:1431\u20131439. https:\/\/doi.org\/10.1093\/rheumatology\/ker113","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR76","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","volume":"71","author":"LK Mercer","year":"2012","unstructured":"Mercer LK, Green AC, Galloway JB et al (2012) The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71:869\u2013874. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200622","journal-title":"Ann Rheum Dis"},{"key":"5136_CR77","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Askling J, Raaschou P et al (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76:386\u2013391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209285","journal-title":"Ann Rheum Dis"},{"key":"5136_CR78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s2468-1253(19)30362-0","volume":"5","author":"AK Waljee","year":"2020","unstructured":"Waljee AK, Higgins PDR, Jensen CB et al (2020) Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. The Lancet Gastroenterology & Hepatology 5:276\u2013284. https:\/\/doi.org\/10.1016\/s2468-1253(19)30362-0","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"5136_CR79","doi-asserted-by":"publisher","unstructured":"Evangelatos G, Koulouri V, Iliopoulos A, et al (2020) Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 12: 1759720X20930116. https:\/\/doi.org\/10.1177\/1759720X20930116.","DOI":"10.1177\/1759720X20930116"},{"key":"5136_CR80","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00296-017-3690-9","volume":"37","author":"SJ Liang","year":"2017","unstructured":"Liang SJ, Zheng QY, Yang YL et al (2017) Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int 37:1207\u20131212. https:\/\/doi.org\/10.1007\/s00296-017-3690-9","journal-title":"Rheumatol Int"},{"key":"5136_CR81","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5114\/ada.2020.96910","volume":"37","author":"A Narcisi","year":"2020","unstructured":"Narcisi A, Bernardini N, Orsini D et al (2020) Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Postepy Dermatol Alergol 37:428\u2013434. https:\/\/doi.org\/10.5114\/ada.2020.96910","journal-title":"Postepy Dermatol Alergol"},{"key":"5136_CR82","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/1756-185X.14034","volume":"24","author":"S Fidan","year":"2021","unstructured":"Fidan S, Capkin E, Arica DA et al (2021) Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis 24:254\u2013259. https:\/\/doi.org\/10.1111\/1756-185X.14034","journal-title":"Int J Rheum Dis"},{"key":"5136_CR83","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2014-206711","volume":"74","author":"YM Chen","year":"2015","unstructured":"Chen YM, Chen HH, Chen YH et al (2015) A comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis 74:626\u2013627. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206711","journal-title":"Ann Rheum Dis"},{"key":"5136_CR84","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A et al (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513\u20132518. https:\/\/doi.org\/10.1002\/art.21233","journal-title":"Arthritis Rheum"},{"key":"5136_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1684\/ejd.2021.4056","volume":"31","author":"A Karamanakos","year":"2021","unstructured":"Karamanakos A, Vergou T, Panopoulos S et al (2021) Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-alpha therapy. Eur J Dermatol 31:307\u2013317. https:\/\/doi.org\/10.1684\/ejd.2021.4056","journal-title":"Eur J Dermatol"},{"key":"5136_CR86","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00296-019-04394-6","volume":"39","author":"L Hasikova","year":"2019","unstructured":"Hasikova L, Pavlikova M, Hulejova H et al (2019) Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Rheumatol Int 39:1749\u20131757. https:\/\/doi.org\/10.1007\/s00296-019-04394-6","journal-title":"Rheumatol Int"},{"key":"5136_CR87","doi-asserted-by":"publisher","unstructured":"Zabihiyeganeh M, Mirzaei AM, Jahed SA (2018) AB1010\u2005Risk of infection in patients with rheumatoid arthritis taking denosumab concurrent with biologic therapy. 1624.2-. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.1317.","DOI":"10.1136\/annrheumdis-2018-eular.1317"},{"key":"5136_CR88","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/art.39075","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Xie F, Yun H et al (2015) Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol 67:1456\u20131464. https:\/\/doi.org\/10.1002\/art.39075","journal-title":"Arthritis Rheumatol"},{"issue":"234\u201341","key":"5136_CR89","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cgh.2015.08.039","volume":"14","author":"G Broms","year":"2016","unstructured":"Broms G, Granath F, Ekbom A et al (2016) Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol 14(234\u201341):e1-5. https:\/\/doi.org\/10.1016\/j.cgh.2015.08.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5136_CR90","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ajog.2019.02.027","volume":"220","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N et al (2019) Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association IBD parenthood project working group. Am J Obstet Gynecol 220:308\u2013323. https:\/\/doi.org\/10.1016\/j.ajog.2019.02.027","journal-title":"Am J Obstet Gynecol"},{"key":"5136_CR91","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208840","journal-title":"Ann Rheum Dis"},{"key":"5136_CR92","doi-asserted-by":"publisher","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, et al (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11: 286\u201392; quiz e24. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.011.","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"5136_CR93","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00296-020-04518-3","volume":"40","author":"OA Uyaroglu","year":"2020","unstructured":"Uyaroglu OA, Seyhoglu E, Erden A et al (2020) Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-alpha biologics: real-life results from a single-centre cross-sectional study. Rheumatol Int 40:1501\u20131507. https:\/\/doi.org\/10.1007\/s00296-020-04518-3","journal-title":"Rheumatol Int"},{"key":"5136_CR94","doi-asserted-by":"publisher","unstructured":"Taylor TRP, Galloway J, Davies R, et al (2021) Demyelinating Events Following Initiation of Anti-TNFalpha Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm 8 https:\/\/doi.org\/10.1212\/NXI.0000000000000992.","DOI":"10.1212\/NXI.0000000000000992"},{"key":"5136_CR95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E (2017) CNS demyelination with TNF-alpha blockers. Curr Neurol Neurosci Rep 17:36. https:\/\/doi.org\/10.1007\/s11910-017-0742-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5136_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217935","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Evangelatos G, Arida A et al (2020) Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217935","journal-title":"Ann Rheum Dis"},{"key":"5136_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641295","volume":"12","author":"E Keewan","year":"2021","unstructured":"Keewan E, Beg S, Naser SA (2021) Anti-TNF-alpha agents modulate SARS-CoV-2 receptors and increase the risk of infection through notch-1 signaling. Front Immunol 12:641295. https:\/\/doi.org\/10.3389\/fimmu.2021.641295","journal-title":"Front Immunol"},{"key":"5136_CR98","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 79:859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"5136_CR99","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00296-021-04803-9","volume":"41","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liu J, Shao R et al (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41:851\u2013861. https:\/\/doi.org\/10.1007\/s00296-021-04803-9","journal-title":"Rheumatol Int"},{"key":"5136_CR100","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15003","volume":"34","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schonmann Y, Damiani G et al (2021) Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol Ther 34:e15003. https:\/\/doi.org\/10.1111\/dth.15003","journal-title":"Dermatol Ther"},{"key":"5136_CR101","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002267","author":"G Bamias","year":"2021","unstructured":"Bamias G, Kokkotis G, Christidou A et al (2021) The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD. Eur J Gastroenterol Hepatol. https:\/\/doi.org\/10.1097\/MEG.0000000000002267","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5136_CR102","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10067-020-05275-1","volume":"39","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Zimba O, Gasparyan AY (2020) Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow\u2019s triad. Clin Rheumatol 39:2529\u20132543. https:\/\/doi.org\/10.1007\/s10067-020-05275-1","journal-title":"Clin Rheumatol"},{"key":"5136_CR103","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3389\/fimmu.2020.02055","volume":"11","author":"T Icenogle","year":"2020","unstructured":"Icenogle T (2020) COVID-19: infection or autoimmunity. Front Immunol 11:2055. https:\/\/doi.org\/10.3389\/fimmu.2020.02055","journal-title":"Front Immunol"},{"key":"5136_CR104","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200160","volume":"10","author":"A Fara","year":"2020","unstructured":"Fara A, Mitrev Z, Rosalia RA et al (2020) Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol 10:200160. https:\/\/doi.org\/10.1098\/rsob.200160","journal-title":"Open Biol"},{"key":"5136_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.833967","volume":"10","author":"Y Guo","year":"2022","unstructured":"Guo Y, Hu K, Li Y et al (2022) Targeting TNF-alpha for COVID-19: Recent Advanced and Controversies. Front Public Health 10:833967. https:\/\/doi.org\/10.3389\/fpubh.2022.833967","journal-title":"Front Public Health"},{"key":"5136_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107961","volume":"99","author":"A Fakharian","year":"2021","unstructured":"Fakharian A, Barati S, Mirenayat M et al (2021) Evaluation of adalimumab effects in managing severe cases of COVID-19: a randomized controlled trial. Int Immunopharmacol 99:107961. https:\/\/doi.org\/10.1016\/j.intimp.2021.107961","journal-title":"Int Immunopharmacol"},{"key":"5136_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena A, Mishra S, Deepak P et al (2022) Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev 21:102927. https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","journal-title":"Autoimmun Rev"},{"key":"5136_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220289","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Ruddy JA, Connolly CM et al (2021) Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220289","journal-title":"Ann Rheum Dis"},{"key":"5136_CR109","doi-asserted-by":"publisher","unstructured":"Evangelatos G, Kouna K, Fragoulis GE, et al (2021) Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab- treated patients: Comment on article of Simon et al. Arthritis Rheumatol https:\/\/doi.org\/10.1002\/art.42011.","DOI":"10.1002\/art.42011"},{"key":"5136_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811829","volume":"9","author":"M Benucci","year":"2022","unstructured":"Benucci M, Damiani A, Infantino M et al (2022) Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: Can therapy affect the immunological response? Front Med (Lausanne) 9:811829. https:\/\/doi.org\/10.3389\/fmed.2022.811829","journal-title":"Front Med (Lausanne)"},{"key":"5136_CR111","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2665-9913(21)00393-3","volume":"4","author":"J Smetanova","year":"2022","unstructured":"Smetanova J, Strizova Z, Sediva A et al (2022) Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol 4:e163\u2013e166. https:\/\/doi.org\/10.1016\/S2665-9913(21)00393-3","journal-title":"Lancet Rheumatol"},{"key":"5136_CR112","doi-asserted-by":"publisher","unstructured":"Geisen UM, Sumbul M, Tran F, et al (2021) Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open 7 https:\/\/doi.org\/10.1136\/rmdopen-2021-002008.","DOI":"10.1136\/rmdopen-2021-002008"},{"key":"5136_CR113","doi-asserted-by":"publisher","unstructured":"Vollenberg R, Tepasse PR, Kuhn JE, et al (2022) Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 10 https:\/\/doi.org\/10.3390\/biomedicines10010171.","DOI":"10.3390\/biomedicines10010171"},{"key":"5136_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.030","author":"A Jena","year":"2022","unstructured":"Jena A, James D, Singh AK et al (2022) Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5136_CR115","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P et al (2017) Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390:2779\u20132789. https:\/\/doi.org\/10.1016\/S0140-6736(17)32641-7","journal-title":"Lancet"},{"key":"5136_CR116","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. The Lancet 364:263\u2013269. https:\/\/doi.org\/10.1016\/s0140-6736(04)16676-2","journal-title":"The Lancet"},{"key":"5136_CR117","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen SM, Jacobs JW, van der Veen MJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443\u20131449. https:\/\/doi.org\/10.1136\/ard.2007.071092","journal-title":"Ann Rheum Dis"},{"key":"5136_CR118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","volume":"15","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R (2019) Treat-to-target in rheumatoid arthritis\u2014Are we there yet? Nat Rev Rheumatol 15:180\u2013186. https:\/\/doi.org\/10.1038\/s41584-019-0170-5","journal-title":"Nat Rev Rheumatol"},{"key":"5136_CR119","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/s0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. The Lancet 386:2489\u20132498. https:\/\/doi.org\/10.1016\/s0140-6736(15)00347-5","journal-title":"The Lancet"},{"key":"5136_CR120","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto A, L\u00f3pez-Medina C, Van den Bosch FE et al (2021) Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis 80:1436\u20131444. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219585","journal-title":"Ann Rheum Dis"},{"key":"5136_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05086-w","author":"Y Nakayama","year":"2022","unstructured":"Nakayama Y, Watanabe R, Murakami K et al (2022) Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-021-05086-w","journal-title":"Rheumatol Int"},{"key":"5136_CR122","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4081\/reumatismo.2013.721","volume":"65","author":"S Bello","year":"2014","unstructured":"Bello S, Bonali C, Serafino L et al (2014) Intra-articular therapy with tumor necrosis factor-alpha antagonists: an update. Reumatismo 65:257\u2013263. https:\/\/doi.org\/10.4081\/reumatismo.2013.721","journal-title":"Reumatismo"},{"key":"5136_CR123","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/PPA.S70834","volume":"9","author":"SC Bolge","year":"2015","unstructured":"Bolge SC, Goren A, Tandon N (2015) Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence 9:121\u2013131. https:\/\/doi.org\/10.2147\/PPA.S70834","journal-title":"Patient Prefer Adherence"},{"key":"5136_CR124","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1060028016682330","volume":"51","author":"MH Garcia-Lagunar","year":"2017","unstructured":"Garcia-Lagunar MH, Gutierrez-Civicos MR, Garcia-Simon MS et al (2017) Reasons for discontinuation and adverse effects of TNFalpha inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother 51:388\u2013393. https:\/\/doi.org\/10.1177\/1060028016682330","journal-title":"Ann Pharmacother"},{"key":"5136_CR125","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S et al (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1113\u20131136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210713","journal-title":"Ann Rheum Dis"},{"key":"5136_CR126","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Brocq O, Perdriger A et al (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first Anti-TNF drug: a randomized clinical trial. JAMA 316:1172\u20131180. https:\/\/doi.org\/10.1001\/jama.2016.13512","journal-title":"JAMA"},{"key":"5136_CR127","doi-asserted-by":"publisher","unstructured":"Todoerti M, Favalli EG, Iannone F, et al (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford) 57: vii42-vii53. https:\/\/doi.org\/10.1093\/rheumatology\/key195.","DOI":"10.1093\/rheumatology\/key195"},{"key":"5136_CR128","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/14397595.2014.953668","volume":"25","author":"T Kobayakawa","year":"2015","unstructured":"Kobayakawa T, Kojima T, Takahashi N et al (2015) Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Mod Rheumatol 25:251\u2013256. https:\/\/doi.org\/10.3109\/14397595.2014.953668","journal-title":"Mod Rheumatol"},{"key":"5136_CR129","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","volume":"79","author":"R Micheroli","year":"2020","unstructured":"Micheroli R, Tellenbach C, Scherer A et al (2020) Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the swiss clinical quality management cohort. Ann Rheum Dis 79:1203\u20131209. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215934","journal-title":"Ann Rheum Dis"},{"key":"5136_CR130","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landewe R et al (2020) Efficacy and safety of ixekizumab through 52\u00a0weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 79:176\u2013185. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216118","journal-title":"Ann Rheum Dis"},{"key":"5136_CR131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2019) Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 71:5\u201332. https:\/\/doi.org\/10.1002\/art.40726","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR132","doi-asserted-by":"publisher","unstructured":"Gisbert JP, Chaparro M (2021) Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 10 https:\/\/doi.org\/10.3390\/jcm10225318.","DOI":"10.3390\/jcm10225318"},{"key":"5136_CR133","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M (2015) An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 28:390\u2013403. https:\/\/doi.org\/10.1111\/dth.12267","journal-title":"Dermatol Ther"},{"key":"5136_CR134","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","volume":"47","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C et al (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 47:183\u2013192. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.008","journal-title":"Semin Arthritis Rheum"},{"key":"5136_CR135","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210262","author":"JF Wu","year":"2021","unstructured":"Wu JF (2021) Therapeutic drug monitoring of biologics for patients with inflammatory bowel diseases: How, When, and for Whom? Gut Liver. https:\/\/doi.org\/10.5009\/gnl210262","journal-title":"Gut Liver"},{"key":"5136_CR136","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, Jorgensen KK, Goll GL et al (2021) Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA 326:2375\u20132384. https:\/\/doi.org\/10.1001\/jama.2021.21316","journal-title":"JAMA"},{"key":"5136_CR137","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H (2017) Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol 13:707\u2013718. https:\/\/doi.org\/10.1038\/nrrheum.2017.187","journal-title":"Nat Rev Rheumatol"},{"key":"5136_CR138","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12760","volume":"32","author":"A Owczarczyk-Saczonek","year":"2019","unstructured":"Owczarczyk-Saczonek A, Owczarek W, Osmola-Mankowska A et al (2019) Secondary failure of TNF-alpha inhibitors in clinical practice. Dermatol Ther 32:e12760. https:\/\/doi.org\/10.1111\/dth.12760","journal-title":"Dermatol Ther"},{"key":"5136_CR139","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","volume":"77","author":"S Bitoun","year":"2018","unstructured":"Bitoun S, Nocturne G, Ly B et al (2018) Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis 77:1463\u20131470. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213403","journal-title":"Ann Rheum Dis"},{"key":"5136_CR140","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325185","author":"Y Gorelik","year":"2021","unstructured":"Gorelik Y, Freilich S, Gerassy-Vainberg S et al (2021) Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2021-325185","journal-title":"Gut"},{"key":"5136_CR141","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR142","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","volume":"78","author":"E van Mulligen","year":"2019","unstructured":"van Mulligen E, de Jong PHP, Kuijper TM et al (2019) Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis 78:746\u2013753. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214970","journal-title":"Ann Rheum Dis"},{"key":"5136_CR143","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/art.41589","volume":"73","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Emery P, Karis E et al (2021) Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheumatol 73:759\u2013768. https:\/\/doi.org\/10.1002\/art.41589","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR144","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41927-019-0058-7","volume":"3","author":"AA Mangoni","year":"2019","unstructured":"Mangoni AA, Al Okaily F, Almoallim H et al (2019) Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatol 3:10. https:\/\/doi.org\/10.1186\/s41927-019-0058-7","journal-title":"BMC Rheumatol"},{"key":"5136_CR145","doi-asserted-by":"publisher","unstructured":"Tanaka Y (2016) Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford) 55: ii15-ii22. https:\/\/doi.org\/10.1093\/rheumatology\/kew352.","DOI":"10.1093\/rheumatology\/kew352"},{"key":"5136_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000474","volume":"3","author":"J Sigaux","year":"2017","unstructured":"Sigaux J, Bailly F, Hajage D et al (2017) Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial. RMD Open 3:e000474. https:\/\/doi.org\/10.1136\/rmdopen-2017-000474","journal-title":"RMD Open"},{"key":"5136_CR147","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","volume":"74","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Hirata S, Kubo S et al (2015) Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 74:389\u2013395. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204016","journal-title":"Ann Rheum Dis"},{"key":"5136_CR148","first-page":"S22","volume":"31","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S, Saleem B et al (2013) Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 31:S22\u2013S27","journal-title":"Clin Exp Rheumatol"},{"key":"5136_CR149","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Compan","year":"2016","unstructured":"Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E et al (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford) 55:1188\u20131194. https:\/\/doi.org\/10.1093\/rheumatology\/kew033","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR150","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","volume":"79","author":"RB Landewe","year":"2020","unstructured":"Landewe RB, van der Heijde D, Dougados M et al (2020) Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis 79:920\u2013928. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216839","journal-title":"Ann Rheum Dis"},{"key":"5136_CR151","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","volume":"78","author":"W Ye","year":"2018","unstructured":"Ye W, Tucker LJ, Coates LC (2018) Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs 78:1705\u20131715. https:\/\/doi.org\/10.1007\/s40265-018-0994-3","journal-title":"Drugs"},{"key":"5136_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000395","volume":"3","author":"DH Huynh","year":"2017","unstructured":"Huynh DH, Boyd TA, Etzel CJ et al (2017) Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open 3:e000395. https:\/\/doi.org\/10.1136\/rmdopen-2016-000395","journal-title":"RMD Open"},{"key":"5136_CR153","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00296-013-2884-z","volume":"34","author":"E Iglesias","year":"2014","unstructured":"Iglesias E, Torrente-Segarra V, Bou R et al (2014) Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-alpha therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 34:1053\u20131057. https:\/\/doi.org\/10.1007\/s00296-013-2884-z","journal-title":"Rheumatol Int"},{"key":"5136_CR154","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","volume":"33","author":"Y Cai","year":"2013","unstructured":"Cai Y, Liu X, Zhang W et al (2013) Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int 33:2277\u20132282. https:\/\/doi.org\/10.1007\/s00296-012-2642-7","journal-title":"Rheumatol Int"},{"key":"5136_CR155","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ajg.2016.54","volume":"111","author":"JP Gisbert","year":"2016","unstructured":"Gisbert JP, Marin AC, Chaparro M (2016) The risk of relapse after anti-tnf discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 111:632\u2013647. https:\/\/doi.org\/10.1038\/ajg.2016.54","journal-title":"Am J Gastroenterol"},{"key":"5136_CR156","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","volume":"6","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Motoya S, Nakamura S et al (2021) Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 6:429\u2013437. https:\/\/doi.org\/10.1016\/S2468-1253(21)00062-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5136_CR157","doi-asserted-by":"publisher","unstructured":"Little DHW, Tabatabavakili S, Shaffer SR, et al (2020) Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol 115: 1768\u201374. https:\/\/doi.org\/10.14309\/ajg.0000000000000783.","DOI":"10.14309\/ajg.0000000000000783"},{"key":"5136_CR158","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","volume":"149","author":"J Torres","year":"2015","unstructured":"Torres J, Boyapati RK, Kennedy NA et al (2015) Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 149:1716\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.055","journal-title":"Gastroenterology"},{"key":"5136_CR159","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5021\/ad.2019.31.5.495","volume":"31","author":"B Kim","year":"2019","unstructured":"Kim B, Maverakis E, Raychaudhuri SP (2019) Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission? Ann Dermatol 31:495\u2013501. https:\/\/doi.org\/10.5021\/ad.2019.31.5.495","journal-title":"Ann Dermatol"},{"key":"5136_CR160","doi-asserted-by":"publisher","unstructured":"Stinco G, Balato N, Buligan C, et al (2019) A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). G Ital Dermatol Venereol 154: 392\u20139. https:\/\/doi.org\/10.23736\/S0392-0488.18.06156-4.","DOI":"10.23736\/S0392-0488.18.06156-4"},{"key":"5136_CR161","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-2571","volume":"97","author":"K Hansel","year":"2017","unstructured":"Hansel K, Bianchi L, Lanza F et al (2017) Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venereol 97:346\u2013350. https:\/\/doi.org\/10.2340\/00015555-2571","journal-title":"Acta Derm Venereol"},{"key":"5136_CR162","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.40235","volume":"69","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Arida A, Panopoulos S et al (2017) Brief report: drug-free long-term remission in severe behcet\u2019s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol 69:2380\u20132385. https:\/\/doi.org\/10.1002\/art.40235","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR163","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000654","volume":"4","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, den Broeder N, van Herwaarden N et al (2018) Predictive value of serum calprotectin (S100A8\/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open 4:e000654. https:\/\/doi.org\/10.1136\/rmdopen-2018-000654","journal-title":"RMD Open"},{"key":"5136_CR164","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/art.41516","volume":"73","author":"W Tao","year":"2021","unstructured":"Tao W, Concepcion AN, Vianen M et al (2021) Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 73:212\u2013222. https:\/\/doi.org\/10.1002\/art.41516","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR165","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab521","author":"N Yoosuf","year":"2021","unstructured":"Yoosuf N, Maciejewski M, Ziemek D et al (2021) Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab521","journal-title":"Rheumatology (Oxford)"},{"key":"5136_CR166","doi-asserted-by":"publisher","unstructured":"Gole B, Potocnik U (2019) Pre-Treatment biomarkers of anti-tumour necrosis factor therapy response in crohn's disease-a systematic review and gene ontology analysis. Cells 8 https:\/\/doi.org\/10.3390\/cells8060515.","DOI":"10.3390\/cells8060515"},{"key":"5136_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102391","volume":"18","author":"G Evangelatos","year":"2019","unstructured":"Evangelatos G, Fragoulis GE, Koulouri V et al (2019) MicroRNAs in rheumatoid arthritis: from pathogenesis to clinical impact. Autoimmun Rev 18:102391. https:\/\/doi.org\/10.1016\/j.autrev.2019.102391","journal-title":"Autoimmun Rev"},{"key":"5136_CR168","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","volume":"3","author":"R Atreya","year":"2018","unstructured":"Atreya R, Neurath MF (2018) Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 3:790\u2013802. https:\/\/doi.org\/10.1016\/S2468-1253(18)30265-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5136_CR169","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","volume":"68","author":"R Gaujoux","year":"2019","unstructured":"Gaujoux R, Starosvetsky E, Maimon N et al (2019) Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD. Gut 68:604\u2013614. https:\/\/doi.org\/10.1136\/gutjnl-2017-315494","journal-title":"Gut"},{"key":"5136_CR170","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/gut.2009.178665","volume":"58","author":"I Arijs","year":"2009","unstructured":"Arijs I, Li K, Toedter G et al (2009) Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58:1612\u20131619. https:\/\/doi.org\/10.1136\/gut.2009.178665","journal-title":"Gut"},{"key":"5136_CR171","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/ibd.21301","volume":"16","author":"I Arijs","year":"2010","unstructured":"Arijs I, Quintens R, Van Lommel L et al (2010) Predictive value of epithelial gene expression profiles for response to infliximab in Crohn\u2019s disease. Inflamm Bowel Dis 16:2090\u20132098. https:\/\/doi.org\/10.1002\/ibd.21301","journal-title":"Inflamm Bowel Dis"},{"key":"5136_CR172","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W et al (2019) Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut 68:814\u2013828. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671","journal-title":"Gut"},{"key":"5136_CR173","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7150\/ijms.22812","volume":"15","author":"P Romero-Cara","year":"2018","unstructured":"Romero-Cara P, Torres-Moreno D, Pedregosa J et al (2018) A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF. Int J Med Sci 15:10\u201315. https:\/\/doi.org\/10.7150\/ijms.22812","journal-title":"Int J Med Sci"},{"key":"5136_CR174","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","volume":"158","author":"A Sazonovs","year":"2020","unstructured":"Sazonovs A, Kennedy NA, Moutsianas L et al (2020) HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with crohn\u2019s disease. Gastroenterology 158:189\u2013199. https:\/\/doi.org\/10.1053\/j.gastro.2019.09.041","journal-title":"Gastroenterology"},{"key":"5136_CR175","doi-asserted-by":"publisher","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Alten R, Cummings F et al (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 13:1868078. https:\/\/doi.org\/10.1080\/19420862.2020.1868078","journal-title":"MAbs"},{"key":"5136_CR176","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.drudis.2019.03.016","volume":"24","author":"SW Burchiel","year":"2019","unstructured":"Burchiel SW, Aspbury R, Munday J (2019) The search for biosimilars and biobetters. Drug Discov Today 24:1087\u20131091. https:\/\/doi.org\/10.1016\/j.drudis.2019.03.016","journal-title":"Drug Discov Today"},{"key":"5136_CR177","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000900","volume":"5","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Goncalves J, Quinn M et al (2019) Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 5:e000900. https:\/\/doi.org\/10.1136\/rmdopen-2019-000900","journal-title":"RMD Open"},{"key":"5136_CR178","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD et al (2018) Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 14:727\u2013740. https:\/\/doi.org\/10.1038\/s41584-018-0110-9","journal-title":"Nat Rev Rheumatol"},{"key":"5136_CR179","doi-asserted-by":"publisher","unstructured":"Kravvariti E, Kitas GD, Sfikakis PP (2019) The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice. Mediterr J Rheumatol 30: 63\u20138. https:\/\/doi.org\/10.31138\/mjr.30.1.63.","DOI":"10.31138\/mjr.30.1.63"},{"key":"5136_CR180","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Evangelatos G, Arida A, et al (2020) Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. Mediterr J Rheumatol 31: 288\u201394. https:\/\/doi.org\/10.31138\/mjr.31.3.288.","DOI":"10.31138\/mjr.31.3.288"},{"key":"5136_CR181","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.actbio.2015.05.036","volume":"24","author":"E Korkmaz","year":"2015","unstructured":"Korkmaz E, Friedrich EE, Ramadan MH et al (2015) Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. Acta Biomater 24:96\u2013105. https:\/\/doi.org\/10.1016\/j.actbio.2015.05.036","journal-title":"Acta Biomater"},{"key":"5136_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640070","volume":"12","author":"M Ferrari","year":"2021","unstructured":"Ferrari M, Onuoha SC, Fossati-Jimack L et al (2021) Novel bispecific antibody for synovial-specific target delivery of anti-tnf therapy in rheumatoid arthritis. Front Immunol 12:640070. https:\/\/doi.org\/10.3389\/fimmu.2021.640070","journal-title":"Front Immunol"},{"key":"5136_CR183","doi-asserted-by":"publisher","unstructured":"Gareb B, Otten AT, Frijlink HW, et al (2020) Review: Local Tumor Necrosis Factor-alpha Inhibition in Inflammatory Bowel Disease. Pharmaceutics 12 https:\/\/doi.org\/10.3390\/pharmaceutics12060539.","DOI":"10.3390\/pharmaceutics12060539"},{"key":"5136_CR184","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.apcsb.2019.08.009","volume":"119","author":"OR Griffiths","year":"2020","unstructured":"Griffiths OR, Landon J, Coxon RE et al (2020) Inflammatory bowel disease and targeted oral anti-TNFalpha therapy. Adv Protein Chem Struct Biol 119:157\u2013198. https:\/\/doi.org\/10.1016\/bs.apcsb.2019.08.009","journal-title":"Adv Protein Chem Struct Biol"},{"key":"5136_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118556","volume":"273","author":"X Li","year":"2021","unstructured":"Li X, Yu M, Zhu Z et al (2021) Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. Carbohydr Polym 273:118556. https:\/\/doi.org\/10.1016\/j.carbpol.2021.118556","journal-title":"Carbohydr Polym"},{"key":"5136_CR186","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.7150\/thno.47601","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, Yan J, Wang L et al (2020) Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics 10:10808\u201310822. https:\/\/doi.org\/10.7150\/thno.47601","journal-title":"Theranostics"},{"key":"5136_CR187","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12951-021-01090-1","volume":"19","author":"P Eder","year":"2021","unstructured":"Eder P, Zielinska A, Karczewski J et al (2021) How could nanobiotechnology improve treatment outcomes of anti-TNF-alpha therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnology 19:346. https:\/\/doi.org\/10.1186\/s12951-021-01090-1","journal-title":"J Nanobiotechnology"},{"key":"5136_CR188","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12896-019-0518-6","volume":"19","author":"MJ Chiabai","year":"2019","unstructured":"Chiabai MJ, Almeida JF, de Azevedo MGD et al (2019) Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice. BMC Biotechnol 19:38. https:\/\/doi.org\/10.1186\/s12896-019-0518-6","journal-title":"BMC Biotechnol"},{"key":"5136_CR189","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.1199214","volume":"332","author":"W Tang","year":"2011","unstructured":"Tang W, Lu Y, Tian QY et al (2011) The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332:478\u2013484. https:\/\/doi.org\/10.1126\/science.1199214","journal-title":"Science"},{"key":"5136_CR190","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/nm1304","volume":"11","author":"GM Deng","year":"2005","unstructured":"Deng GM, Zheng L, Chan FK et al (2005) Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 11:1066\u20131072. https:\/\/doi.org\/10.1038\/nm1304","journal-title":"Nat Med"},{"key":"5136_CR191","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1002\/art.27534","volume":"62","author":"GM Deng","year":"2010","unstructured":"Deng GM, Liu L, Tsokos GC (2010) Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL\/lpr mice. Arthritis Rheum 62:2424\u20132431. https:\/\/doi.org\/10.1002\/art.27534","journal-title":"Arthritis Rheum"},{"key":"5136_CR192","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/art.39816","volume":"68","author":"A Williams","year":"2016","unstructured":"Williams A, Wang ECY, Thurner L et al (2016) Review: novel insights into tumor necrosis factor receptor, death receptor 3, and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68:2845\u20132856. https:\/\/doi.org\/10.1002\/art.39816","journal-title":"Arthritis & Rheumatology"},{"key":"5136_CR193","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/art.38755","volume":"66","author":"FE McCann","year":"2014","unstructured":"McCann FE, Perocheau DP, Ruspi G et al (2014) Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol 66:2728\u20132738. https:\/\/doi.org\/10.1002\/art.38755","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR194","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1016\/j.biomaterials.2009.08.041","volume":"30","author":"H Shibata","year":"2009","unstructured":"Shibata H, Yoshioka Y, Abe Y et al (2009) The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30:6638\u20136647. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.08.041","journal-title":"Biomaterials"},{"key":"5136_CR195","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/srep03153","volume":"3","author":"Y Okubo","year":"2013","unstructured":"Okubo Y, Mera T, Wang L et al (2013) Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep 3:3153. https:\/\/doi.org\/10.1038\/srep03153","journal-title":"Sci Rep"},{"key":"5136_CR196","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X (2017) Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460. https:\/\/doi.org\/10.3389\/fphar.2017.00460","journal-title":"Front Pharmacol"},{"key":"5136_CR197","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cytogfr.2020.03.002","volume":"55","author":"N Zhang","year":"2020","unstructured":"Zhang N, Wang Z, Zhao Y (2020) Selective inhibition of tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. Cytokine Growth Factor Rev 55:80\u201385. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.03.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"5136_CR198","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fcell.2020.00401","volume":"8","author":"R Fischer","year":"2020","unstructured":"Fischer R, Kontermann RE, Pfizenmaier K (2020) Selective targeting of TNF receptors as a novel therapeutic approach. Front Cell Dev Biol 8:401. https:\/\/doi.org\/10.3389\/fcell.2020.00401","journal-title":"Front Cell Dev Biol"},{"key":"5136_CR199","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/JLB.2AB0420-572RR","volume":"109","author":"N Weinelt","year":"2021","unstructured":"Weinelt N, Karathanasis C, Smith S et al (2021) Quantitative single-molecule imaging of TNFR1 reveals zafirlukast as antagonist of TNFR1 clustering and TNFalpha-induced NF-kB signaling. J Leukoc Biol 109:363\u2013371. https:\/\/doi.org\/10.1002\/JLB.2AB0420-572RR","journal-title":"J Leukoc Biol"},{"key":"5136_CR200","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1038\/s41467-019-13616-1","volume":"10","author":"J O'Connell","year":"2019","unstructured":"O\u2019Connell J, Porter J, Kroeplien B et al (2019) Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer. Nat Commun 10:5795. https:\/\/doi.org\/10.1038\/s41467-019-13616-1","journal-title":"Nat Commun"},{"key":"5136_CR201","doi-asserted-by":"publisher","unstructured":"Papadopoulou D, Drakopoulos A, Lagarias P, et al (2021) In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes. Int J Mol Sci 22 https:\/\/doi.org\/10.3390\/ijms221910220.","DOI":"10.3390\/ijms221910220"},{"key":"5136_CR202","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-021-02764-y","volume":"19","author":"L Ntari","year":"2021","unstructured":"Ntari L, Nikolaou C, Kranidioti K et al (2021) Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment. J Transl Med 19:165. https:\/\/doi.org\/10.1186\/s12967-021-02764-y","journal-title":"J Transl Med"},{"key":"5136_CR203","first-page":"406","volume":"17","author":"SL Gold","year":"2021","unstructured":"Gold SL, Steinlauf AF (2021) Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol Hepatol (N Y) 17:406\u2013414","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"5136_CR204","doi-asserted-by":"publisher","unstructured":"Hammoura I, Fiechter RH, Bryant SH, et al (2022) Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis. Int J Mol Sci 23 https:\/\/doi.org\/10.3390\/ijms23020859.","DOI":"10.3390\/ijms23020859"},{"key":"5136_CR205","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/art.30418","volume":"63","author":"MI Koenders","year":"2011","unstructured":"Koenders MI, Marijnissen RJ, Devesa I et al (2011) Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 63:2329\u20132339. https:\/\/doi.org\/10.1002\/art.30418","journal-title":"Arthritis Rheum"},{"key":"5136_CR206","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/art.38896","volume":"67","author":"JA Fischer","year":"2015","unstructured":"Fischer JA, Hueber AJ, Wilson S et al (2015) Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 67:51\u201362. https:\/\/doi.org\/10.1002\/art.38896","journal-title":"Arthritis Rheumatol"},{"key":"5136_CR207","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3389\/fimmu.2017.01073","volume":"8","author":"MA Nosenko","year":"2017","unstructured":"Nosenko MA, Atretkhany KN, Mokhonov VV et al (2017) VHH-based bispecific antibodies targeting cytokine production. Front Immunol 8:1073. https:\/\/doi.org\/10.3389\/fimmu.2017.01073","journal-title":"Front Immunol"},{"key":"5136_CR208","doi-asserted-by":"publisher","first-page":"1770018","DOI":"10.1080\/19420862.2020.1770018","volume":"12","author":"S Zheng","year":"2020","unstructured":"Zheng S, Shen F, Jones B et al (2020) Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. MAbs 12:1770018. https:\/\/doi.org\/10.1080\/19420862.2020.1770018","journal-title":"MAbs"},{"key":"5136_CR209","doi-asserted-by":"publisher","unstructured":"Stoffel B, McPherson M, Hernandez A, et al (2021) Pos0365\u2005Anti-Tnf Glucocorticoid Receptor Modulator Antibody Drug Conjugate for the Treatment of Autoimmune Diseases. Annals of the Rheumatic Diseases 80: 412.2\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2213.","DOI":"10.1136\/annrheumdis-2021-eular.2213"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05136-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:03:05Z","timestamp":1659484985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05136-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":209,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5136"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05136-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No part of this review, including ideas and tables, is copied or published elsewhere.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GE declares no conflicts of interest for this review. GB has received advisor, lecturer and research grants from Abbvie, Adacyte Therapeutics, Aenorasis, Amgen, Cooper, Ferring, Genesis Pharma, Janssen, MSD, Mylan, Pfizer, Takeda, Vianex. GDK declares no conflicts of interest for this review. GK declares no conflicts of interest for this review. PPS has served as a consultant or on an advisory board and has received grant and research support from Abbvie, Actelion, Amgen, Boehringer Ingelheim, Enorasis, Faran, Pharmaserve-Lilly, Genesis Pharma, Gilead, Janssen, MSD, Novartis, Pfizer, Roche and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}